Pension & Wealth provides wealth management solutions, investment management, retirement planning, and estate planning services, focusing on risk management and comprehensive financial solutions for individuals and institutions.

Pension & Wealth

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

George Rathmann

Amgen Inc.

The Boeing Company, together with its subsidiaries, designs, develops, manufactures, sales, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight and launch systems, and services worldwide. The company operates through four segments: Commercial Airplanes; Defense, Space & Security; Global Services; and Boeing Capital. The Commercial Airplanes segment provides commercial jet aircraft for passenger and cargo requirements, as well as fleet support services. The Defense, Space & Security segment engages in the research, development, production, and modification of manned and unmanned military aircraft and weapons systems; strategic defense and intelligence systems, which include strategic missile and defense systems, command, control, communications, computers, intelligence, surveillance and reconnaissance, cyber and information solutions, and intelligence systems; and satellite systems, such as government and commercial satellites, and space exploration. The Global Services segment offers products and services, including supply chain and logistics management, engineering, maintenance and modifications, upgrades and conversions, spare parts, pilot and maintenance training systems and services, technical and maintenance documents, and data analytics and digital services to commercial and defense customers. The Boeing Capital segment offers financing services and manages financing exposure for a portfolio of equipment under operating leases, sales-type/finance leases, notes and other receivables, assets held for sale or re-lease, and investments. The company was incorporated in 1916 and is based in Chicago, Illinois.

William Edward Boeing

The Boeing Company

ConocoPhillips explores for, develops, and produces crude oil and natural gas globally.

Metric
Company Name	Pension & Wealth	Amgen Inc.	The Boeing Company	ConocoPhillips
Symbol		AMGN	BA
MSH ID	COM:PENSIONWEALTH	COM:AMGEN	COM:BOEING	COM:CONOCOPHILLIPS
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Financial Services & Finance	Healthcare	Industrials	Energy
Industry	Financial Planning and Advisory Services	Drug Manufacturers - General	Aerospace & Defense	Oil & Gas Exploration & Production
Country	US	US	US	US
Stage
Employee Count		26.70K	171K
Website	pensionwealth.com	amgen.com	boeing.com	conocophillips.com
LinkedIn		amgen	boeing
Founders

Metric
Market Cap		172.56B	113.08B
Enterprise Value
Monthly Web Traffic	325	1.00M
Web Traffic Growth	22.21	-0.02
Valuation
Raised Capital		28.50B

Metric
Revenue	28.19B	77.79B
Revenue (LTM)
Revenue (NTM)
Gross Profit	19.74B	7.72B
EBITDA	7.90B	-773M
Operating Income	7.90B	-773M
Net Income	6.72B	-2.22B
EPS	12.56	-3.67
Diluted EPS	12.49	-3.67
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.70	0.10
Operating Profit Margin	0.32	-0.01
EBITDA Margin	0.28	-0.01
Net Profit Margin	0.24	-0.03
Return on Equity	1.03	0.20
Return on Assets	0.07	-0.02
Return on Capital Employed	0.12	-0.01

COM:PENSIONWEALTH

Pension & Wealth

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	22.81	-56.42
P/B Ratio	22.55	-7.31
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.11	1.58
EV Multiple	12.57	301.02

Metric
Days Sales Outstanding	83.59	51.92
Days Payables Outstanding	69.95	62.32
Days Inventory Outstanding	411.08	469.70
Operating Cycle	513.92	533.59
Cash Conversion Cycle	445.24	468.54
Asset Turnover	0.34	0.57

Metric
Operating Cash Flow	8.47B	5.96B
Free Cash Flow	7.36B	4.43B
Cash Flow to Debt	0.13	0.11
Operating Cash Flow/Sales	0.30	0.08
Free Cash Flow Yield	0.06	0.01

Metric
Cash & Equivalents	10.94B	12.69B
Accounts Receivable	-1.01B	-128M
Inventory	9.52B	79.74B
Goodwill	18.63B	8.09B
Debt to Capitalization	0.93	1.55
Debt to Assets	0.67	0.38
Current Ratio	2.86	1.14
Quick Ratio	1.62	0.30

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03	0.01
R&D to Revenue	0.17	0.04
SG&A to Revenue		0.07